AbbVie Inc (NYSE:ABBV) – Investment analysts at Leerink Swann increased their FY2019 earnings per share estimates for AbbVie in a report released on Thursday. Leerink Swann analyst G. Porges now expects that the company will earn $9.37 per share for the year, up from their previous estimate of $8.36. Leerink Swann currently has a “Buy” rating and a $106.00 target price on the stock.

Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Monday. Argus lifted their price objective on shares of AbbVie from $90.00 to $110.00 and gave the company a “buy” rating in a report on Friday, September 29th. UBS Group lowered shares of AbbVie from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $79.00 to $92.00 in a report on Monday, September 25th. Jefferies Group reaffirmed a “buy” rating and issued a $107.00 price target on shares of AbbVie in a report on Thursday, September 28th. Finally, Barclays reaffirmed a “hold” rating and issued a $68.00 price target on shares of AbbVie in a report on Thursday, September 28th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $101.38.

Shares of AbbVie (ABBV) traded up $1.29 during mid-day trading on Monday, reaching $105.93. 1,969,187 shares of the company traded hands, compared to its average volume of 5,044,423. The stock has a market capitalization of $169,010.00, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 1.22 and a beta of 1.53. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie has a 12 month low of $59.27 and a 12 month high of $104.87.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company posted $1.21 earnings per share.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.68%. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is currently 68.93%.

In other news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction on Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the sale, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders sold 494,676 shares of company stock worth $47,237,938 over the last ninety days. Corporate insiders own 0.23% of the company’s stock.

Large investors have recently bought and sold shares of the company. Cornerstone Investment Partners LLC lifted its position in AbbVie by 100.0% during the fourth quarter. Cornerstone Investment Partners LLC now owns 31,470 shares of the company’s stock valued at $3,043,000 after purchasing an additional 15,735 shares during the period. Steward Partners Investment Advisory LLC lifted its position in AbbVie by 2.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 66,316 shares of the company’s stock valued at $6,413,000 after purchasing an additional 1,561 shares during the period. Round Table Services LLC acquired a new position in AbbVie during the fourth quarter valued at $207,000. V Wealth Management LLC lifted its position in AbbVie by 24.3% during the fourth quarter. V Wealth Management LLC now owns 3,892 shares of the company’s stock valued at $399,000 after purchasing an additional 762 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in AbbVie during the fourth quarter valued at $399,000. Institutional investors and hedge funds own 69.22% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/22/fy2019-eps-estimates-for-abbvie-inc-raised-by-leerink-swann-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.